Medicine & Life Sciences
Irinotecan
100%
Colorectal Neoplasms
67%
Oxaliplatin
61%
Fluorouracil
51%
Neoplasms
50%
gemcitabine
45%
Leucovorin
44%
Pharmacokinetics
31%
Erlotinib Hydrochloride
27%
Appointments and Schedules
24%
Therapeutics
24%
Drug Therapy
24%
Paclitaxel
23%
Survival
23%
Carcinoid Tumor
22%
Adenocarcinoma
22%
Melanoma
21%
Diarrhea
20%
Maximum Tolerated Dose
20%
Carboplatin
19%
Pancreatic Neoplasms
19%
Cisplatin
17%
Neutropenia
16%
Radiotherapy
16%
7-ethyl-10-hydroxycamptothecin glucuronide
16%
Bortezomib
16%
Carcinoid Heart Disease
14%
Bevacizumab
14%
Renal Cell Carcinoma
14%
Hepatocellular Carcinoma
14%
Safety
13%
Nausea
13%
Prostatic Neoplasms
13%
Capecitabine
13%
Randomized Controlled Trials
12%
Neoplasm Metastasis
12%
Biliary Tract Neoplasms
12%
Carcinoma
12%
Carmustine
11%
Phase III Clinical Trials
10%
Proteasome Inhibitors
10%
Liver
10%
KW 2189
10%
GRAMLGTHTMEVTV
9%
ISIS 2503
9%
Vomiting
9%
Proxy
9%
N-benzhydryl-5-(2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo(1,2-a)(1,5)diazocine-8-carboxamide
9%
Thrombocytopenia
9%
bizelesin
9%